Programmed Death Ligand 1

QR1, Rb, 1 ml Conc.

Artikelnummer:1-PR292-07
Menge:
Technische Daten
Lagerung AK:Store at 2 - 8 °C. Do not use after expiration date indicated on the vial.
Zelluläre Lokalisation:Cytoplasmic, membranous
Reaktivität AK:Human, others not tested
Format AK:Concentrate
Klon:QR1
Spezies:Rabbit
Ig Unterklasse:IgG1
Immunogen:Synthetic peptide of the PD-L1 protein
Anwendung AK:IHC(p),IHC(f),WB
Fixierung:1) NOTOXhisto 2) Formalin
Kontrolle:PD-L1 transfected HEK cell pellets, non-small cell lung cancer, tonsil
Synonyme:CD274, Programmed cell death 1 ligand 1, Programmed death ligand 1, PD-L1, PDCD1 ligand 1, B7 homolog 1, B7-H1.
Verfügbar in folgenden Ländern:world wide (except US)
Status:IVD
Beschreibung

Programmed Death Ligand 1 (PD-L1), also known as CD274 and B7-H1, is a transmembrane protein expressed on the surface of resting T-cells [1-4]. Binding to its receptor PD-1, a T-cell immune checkpoint, T-cell activation is inhibited and autoimmune reaction is stopped [2,5]. Some tumor cells use this mechanism to prevent apoptosis and obtain resistance against CD8+ Tcell mediated cell lysis [2]. PD-L1 (QR1) is suitable to detect sentinel lymph node melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC) as well as triple-negative breast cancer (TNBC). The antibody produces membranous and/or cytoplasmic staining.

Literatur

[1] Butte MJ, Pena-Cruz V et al. (2008). Mol Immunol. 45(13): 3567-72.
[2] Ostrand-Rosenberg S, Horn LA, Haile ST (2014). J Immunol. 193 (8): 3835-41.
[3] Freeman GJ, Long AJ et al. (2000). J Exp Med. 192(7): 1027-34.
[4] Sharpe AH, Wherry EJ et al. (2007). Nat Immunol. 8(3): 239-45.
[5] Patel SP, Kurzrock R (2015). Mol Cancer Ther. 14(4): 847-56.
[6] Bu_ttner R, Gosney JR et al. (2017). J Clin Oncol. 35(34): 3867-76.
[7] Scheel AH, Baenfer G et al. (2017). Histopathology. doi: 10.1111/his.13375.
[8] Ghorani E, Kaur B et al. (2017). Lancet. 390: 2343-45. Supplementary appendix.
[9] Hofman P (2017). Expert Rev Mol Diagn. 17(12): 1097-1108.
[10] Menguy S, Prochazkova-Carlotti M et al. (2018). Am J Surg Pathol. 42(3): 326-34.
[11] 2017. Der Pathologe. 4: 345-50.
[12] Jöhrens K, BŸttner R et al. QuIP Ring Trial Q1/2017.
[13] Lantuejoul S, Damotte D et al. (2019). J Thorac Dis. 11(Suppl 1): 89-101.
[14] Lantuejoul S, Adam J et al. (2018). Ann Patholr. 38(2): 110-25.
[15] Scimeca M, Bonfiglio R et al. (2019). Urol Oncol. pii: S1078-1439(19)30068-7.
[16] Bianchi A, Annibali O et al. (2019).

Kunden, die sich für diesen Artikel interessierten, interessierten sich auch für:

Kontakt